NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ADAG

Adagene Inc ADR

Jul 11 • 04:00PM ET

1.91

Dollar change -0.03
Percentage change -1.55	%

Healthcare • Biotechnology • China • NASD

Peers: FATE KURA ATNM IMAB ALXO IMTX ANVS VXRT LBPH NRBO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.74	Insider Own	23.85%	Shs Outstand	47.11M	Perf Week	3.24%
Market Cap	89.98M	Forward P/E	-	EPS next Y	-1.03	Insider Trans	0.00%	Shs Float	35.87M	Perf Month	-2.55%
Enterprise Value	23.28M	PEG	-	EPS next Q	-	Inst Own	2.22%	Short Float	0.22%	Perf Quarter	36.43%
Income	-33.38M	P/S	899.80	EPS this Y	-40.68%	Inst Trans	-42.98%	Short Ratio	1.65	Perf Half Y	-7.28%
Sales	0.10M	P/B	1.78	EPS next Y	-24.10%	ROA	-32.56%	Short Interest	0.08M	Perf YTD	-4.02%
Book/sh	1.07	P/C	1.06	EPS next 5Y	-22.33%	ROE	-55.14%	52W High	3.58 -46.66%	Perf Year	-30.55%
Cash/sh	1.81	P/FCF	-	EPS past 3/5Y	25.96% -14.47%	ROIC	-65.35%	52W Low	1.33 44.15%	Perf 3Y	-7.54%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-78.35% -26.47%	Gross Margin	-798.76%	Volatility	6.93% 5.97%	Perf 5Y	-
Dividend TTM	-	EV/Sales	232.80	EPS Y/Y TTM	-69.40%	Oper. Margin	-34881.07%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.30	Sales Y/Y TTM	-99.43%	Profit Margin	-32428.84%	RSI (14)	51.17	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.30	EPS Q/Q	-	SMA20	-0.48%	Beta	0.74	Target Price	3.50
Payout	-	Debt/Eq	0.37	Sales Q/Q	-	SMA50	4.42%	Rel Volume	0.48	Prev Close	1.94
Employees	138	LT Debt/Eq	0.01	Earnings	Mar 24 BMO	SMA200	-4.33%	Avg Volume	46.70K	Price	1.91
IPO	Feb 09, 2021	Option/Short	No / Yes	EPS/Sales Surpr.	12.12% -	Trades		Volume	22,382	Change	-1.55%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-31-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-25-21	Initiated	China Renaissance	Buy	$40.57
Mar-08-21	Initiated	Morgan Stanley	Overweight	$34
Mar-08-21	Initiated	Jefferies	Buy	$33
Mar-08-21	Initiated	Goldman	Buy	$29

Jul-08-25 07:00AM	Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate (GlobeNewswire)
Jul-01-25 07:00AM	Adagene announces up to $25 million strategic investment from Sanofi (GlobeNewswire) -5.13%
Jun-03-25 09:40AM	Is McKesson (MCK) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:30AM	Adagene to Present at Jefferies Global Healthcare Conference 2025 (GlobeNewswire)
May-22-25 05:05PM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire) +12.00%
08:00AM	Loading…
Apr-28-25 08:00AM	Adagene Appoints John Maraganore, Ph.D. as Executive Advisor (GlobeNewswire)
Apr-23-25 10:05AM	Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-07-25 08:00AM	Adagene to Present at Stifel's 2025 Virtual Targeted Oncology Forum (GlobeNewswire)
Mar-24-25 08:00AM	Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire) +5.04%
Mar-13-25 08:00AM	Adagene to Present at 11th Annual Immuno-Oncology 360 Summit (GlobeNewswire)
Mar-06-25 08:00AM	Adagene to Present at Leerink's Global Healthcare Conference 2025 (GlobeNewswire)
Feb-27-25 08:00AM	Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer (GlobeNewswire)
Jan-27-25 07:00AM	Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-21-25 05:00PM	Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium (GlobeNewswire)
Jan-14-25 08:00AM	Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025 (GlobeNewswire)
09:40AM	Loading…
Jan-08-25 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.34%
Dec-06-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Nov-20-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -5.86%
Nov-07-24 10:01AM	Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Oct-09-24 06:00AM	Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting (GlobeNewswire)
Sep-16-24 03:01AM	Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody ADG126 (Muzastotug) in Combination with KEYTRUDA (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) -21.20%
Sep-11-24 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-29-24 07:00AM	Adagene to Participate in Investor Conferences in September (GlobeNewswire)
Aug-26-24 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-25-24 04:05PM	Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update (GlobeNewswire) -7.50%
Jul-12-24 07:00AM	Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September (GlobeNewswire)
May-22-24 04:45PM	Adagene to Present at Investor Conferences in June (GlobeNewswire) +6.90%
Mar-29-24 09:00AM	Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-07-24 04:01PM	Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board (GlobeNewswire)
Feb-27-24 08:00AM	Adagene to Present at the Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
06:00AM	Loading…
Feb-09-24 06:00AM	Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with KEYTRUDA (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +5.14%
Jan-17-24 07:00AM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (PR Newswire) +5.82%
Jan-16-24 05:01PM	Adagene Presents Interim Results Reinforcing Best-in-Class Profile of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC) (GlobeNewswire) +19.24%
Jan-04-24 05:00AM	Adagene To Present Interim Results of Masked anti-CTLA-4 SAFEbody ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at ASCO-GI Symposium (GlobeNewswire)
Nov-03-23 12:00PM	Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody ADG126 at SITC 2023 (GlobeNewswire)
Oct-30-23 09:40AM	Are Medical Stocks Lagging Boston Scientific (BSX) This Year? (Zacks)
Oct-13-23 09:40AM	Are Medical Stocks Lagging Medpace (MEDP) This Year? (Zacks)
Oct-12-23 08:00AM	Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire) -6.04%
Sep-27-23 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks) +10.14%
Sep-07-23 10:45PM	Adagene to Present at Investor and Scientific Conferences in September (PR Newswire)
09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
Aug-31-23 07:32AM	Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update (GlobeNewswire) +15.25%
May-25-23 09:40AM	Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.22%
May-04-23 09:00AM	Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second SAFEbody® Novel Masked Antibody-Drug Conjugate (GlobeNewswire)
Apr-28-23 07:00AM	Adagene Announces Updates to its Board of Directors (GlobeNewswire)
Apr-18-23 09:17AM	Adagene Presents Clinical Data for Anti-CTLA-4 SAFEbody® ADG126 Reinforcing Best-in-Class Safety Profile at Repeat Doses and Showing Early Efficacy Profile in Advanced/Metastatic Solid Tumors (GlobeNewswire)
Mar-31-23 09:40AM	Are Medical Stocks Lagging Adagene (ADAG) This Year? (Zacks)
06:34AM	Adagene Full Year 2022 Earnings: US$1.85 loss per share (vs US$1.83 loss in FY 2021) (Simply Wall St.)
Mar-28-23 04:30PM	Adagene Reports Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire) +5.84%
Mar-14-23 06:00PM	Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April (GlobeNewswire) +5.15% +11.89%
Mar-05-23 07:39PM	Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board (GlobeNewswire)
Jan-09-23 07:00AM	Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-CTLA-4 SAFEbody® ADG126 up to 10 mg/kg with Repeat Cycles in Combination with Anti-PD-1 Therapy from Dose Escalation Portion of Phase 1b/2 Trial (GlobeNewswire) +11.25%
Jan-05-23 04:01PM	Adagene to Present at the Biotech Showcase 2023 in San Francisco on January 9 (GlobeNewswire) +5.11% +11.11%
Dec-16-22 06:30AM	Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbody® ADG126 in Combination with Roches Standard-of-Care for First-Line Advanced Liver Cancer (GlobeNewswire) +10.61%
Nov-21-22 04:05PM	Adagene Appoints Cuong Do to Board of Directors and Audit Committee (GlobeNewswire)
Nov-10-22 09:05AM	Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors (GlobeNewswire)
Oct-11-22 04:03PM	Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancers (SITC) Annual Meeting in November (GlobeNewswire) -7.63% +6.61%
Sep-10-22 04:13AM	Adagene Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors (GlobeNewswire)
Aug-30-22 05:25PM	Adagene Reports Financial Results for the Six Months Ended June 30, 2022 and Provides Corporate Updates (GlobeNewswire)
Jun-29-22 04:05PM	Adagene Announces Authorization of Share Repurchase Program up to US$10 Million (GlobeNewswire)
May-26-22 09:30PM	Adagene Announces Publication at ASCO of Interim Monotherapy Dose Escalation Data Showing Compelling Safety Profile of Anti-CTLA-4 SAFEbody® ADG126, with Repeat Dosing Across Dose Levels (PR Newswire)
May-12-22 07:00AM	Adagene to Participate in Investor Conferences in May and June (GlobeNewswire)
May-02-22 06:06AM	Shareholders in Adagene (NASDAQ:ADAG) are in the red if they invested a year ago (Simply Wall St.)
Apr-08-22 01:09PM	Adagene Presents Data Demonstrating First and Best-in-Class Potential for Differentiated Preclinical Antibody Candidates at American Association for Cancer Research (AACR) Annual Meeting 2022 (GlobeNewswire)
Apr-03-22 02:34PM	10 Best Non-Tech Chinese Stocks to Buy Now (Insider Monkey)
Mar-31-22 08:30AM	Adagene Reports Full Year 2021 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-17-22 10:42AM	Adagene (ADAG) Gets FDA Nod for Cancer Study on ADG126 Combo (Zacks)
Mar-16-22 10:00AM	Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors (Benzinga)
07:00AM	Adagene Announces FDA Clearance to Proceed with Phase 1b/2 Trial of Anti-CTLA-4 ADG126 SAFEbody® in Combination Therapy With Anti-PD-1 Antibody Pembrolizumab (PR Newswire)
Mar-08-22 09:21PM	Adagene Announces Four Poster Presentations on Robust Preclinical Pipeline of Antibody-Based Therapeutics at Upcoming American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Mar-02-22 08:22AM	Sanofi to pay up to $2.5 billion in deal with Adagene (MarketWatch)
06:00AM	Adagene Announces SAFEbody® Multi-Target Collaboration with Sanofi for Novel Masked Immuno-Oncology Antibody Candidates (PR Newswire)
Feb-08-22 07:00AM	Adagene to Participate in the SVB Leerink 11th Annual Global Healthcare Conference (GlobeNewswire)
Feb-02-22 04:05PM	Adagene Announces Board and Management Appointments to Support Pipeline Growth (GlobeNewswire)
Jan-27-22 07:00AM	Adagene Announces First Patient Dosed with Novel, Proprietary Combination of Anti-CD137 Agonist, ADG106, and Anti-CTLA-4 Monoclonal Antibody, ADG116 (GlobeNewswire)
Jan-19-22 07:00AM	Adagene Expands Scientific and Strategic Advisory Board with Appointment of David Gandara, M.D. (GlobeNewswire)
Jan-13-22 04:00AM	Adagene Announces First Patients with Advanced Non-Small Cell Lung Cancer Dosed in Phase 1b/2 Clinical Trial of ADG106 in Combination with Nivolumab in Singapore (GlobeNewswire)
Dec-22-21 04:05PM	Adagene Achieves Key Milestone in Collaboration with Exelixis for SAFEbody® Novel Masked Antibody-Drug Conjugate Candidates (GlobeNewswire) -6.57%
Dec-13-21 10:23AM	Adagene Presents Preclinical Data Showcasing Best-in-Class Profiles for ADG153, an Anti-CD47 SAFEbody® and ADG152, a CD20xCD3 Bispecific T-cell Engager POWERbody (GlobeNewswire) -13.51%
Dec-06-21 01:49PM	Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Cold Tumors Including Pancreatic and Ovarian Cancers for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 (GlobeNewswire) +6.44%
06:30AM	Adagene Presents Clinical Data Demonstrating Strong Safety and Early Signals of Efficacy in Treatment-Resistant Tumors for Anti-CTLA-4 Monoclonal Antibody, ADG116, at ESMO-IO 2021 (GlobeNewswire)
Nov-30-21 04:01PM	Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study (Zacks)
Nov-29-21 04:05PM	Adagene Announces FDA Clearance of IND for Phase 1b/2 Trial of Anti-CTLA-4 Monoclonal Antibody ADG116 in Combination Therapy with Anti-PD-1 Antibody Pembrolizumab (GlobeNewswire)
Nov-22-21 05:05PM	Adagene Announces Poster Presentations of Clinical Data for Two Novel Antibody Programs at ESMO Immuno-Oncology Congress 2021 (GlobeNewswire)
Nov-09-21 04:05PM	Adagene to Participate in Upcoming Investor & Industry Conferences in November (GlobeNewswire) +5.91%
Nov-04-21 09:24AM	Adagene Unveils Preclinical Data from Two Transformative Antibody Programs at Upcoming American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) +5.54%
Oct-27-21 08:52AM	Adagene Establishes Collaboration for Clinical Trial of ADG106 in Combination with Nivolumab in Patients with Non-Small Cell Lung Cancer in Singapore (PR Newswire)
Oct-21-21 08:00AM	Adagene to Participate in the Jefferies Virtual China Biotech Summit (GlobeNewswire)
Sep-17-21 12:22PM	Hedge Funds are Selling These 10 Chinese Stocks Amid Crackdowns (Insider Monkey)
Sep-02-21 07:45AM	Adagene to Participate at the Morgan Stanley 19th Annual Global Healthcare Conference (GlobeNewswire)
Aug-26-21 07:45AM	Adagene Reports Financial Results for the Six Months Ended June 30, 2021 and Provides Corporate Updates (GlobeNewswire)
Aug-19-21 07:37AM	The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck (Benzinga)
07:00AM	Adagene Announces the Third Clinical Trial Collaboration with Merck to Advance Anti-CD137 Agonist, ADG106, in Combination Therapy with KEYTRUDA® (pembrolizumab) (GlobeNewswire)
Aug-12-21 07:45AM	Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board (GlobeNewswire)
Jul-22-21 07:45AM	Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab) (GlobeNewswire)
Jul-12-21 10:15PM	Chinas U.S. IPO Queue to Shrink Amid Regulatory Crackdown (Bloomberg) +6.95% +11.11%
Jul-09-21 10:47AM	20 Chinese Companies Listed on NYSE/NASDAQ/AMEX (Insider Monkey) +5.27%
Jul-07-21 07:45AM	Adagene Announces Authorization of Share Repurchase Program up to US$20 Million (GlobeNewswire) +6.22%
Jun-16-21 04:49PM	Top Chinese Companies on NASDAQ (Insider Monkey)
07:45AM	Adagene Announces Inclusion in FTSE Russell Indexes (GlobeNewswire)

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. Its dynamic precision library platform is composed of the following proprietary technologies: NEObody, SAFEbody, and POWERbody. The company was founded by Ge Li and Pei Zhi Luo on February 25, 2011 and is headquartered in Suzhou, China.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADAG

Adagene Inc ADR

Upgrade your FINVIZ experience